Galmed Pharmaceuticals Ltd.
EOCN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595353
No open-market purchases or sales by Galmed Pharmaceuticals Ltd. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $85.9K in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Galmed Pharmaceuticals Ltd. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 12 | 17 | +5 |
| Shares | 143.5K | 691.4K | +547.9K (+381.7%) |
| Value | $419.1K | $428.2K | +$9.06K (+2.2%) |
New holders (8)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Walleye Capital LLC | 249,763 | $154.9K | 0.00% |
| CVI Holdings, LLC | 249,384 | $154.6K | 0.31% |
| Two Sigma Advisers, LP | 50,633 | $31.4K | 0.00% |
| Citadel Advisors LLC | 40,458 | $25.1K | 0.00% |
| Two Sigma Investments, LP | 30,720 | $19.0K | 0.00% |
| Virtu Financial LLC | 29,608 | $18.0K | 0.00% |
| Advisor Group Holdings, Inc. | 53 | $32 | 0.00% |
| Bank of America Corp | 1 | $1 | 0.00% |
Sold out (3)
Institutions that held Galmed Pharmaceuticals Ltd. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| BVF Inc | 89,853 | $261.5K |
| Susquehanna International Group, LLP | 25,597 | $74.5K |
| Tower Research Capital LLC (TRC) | 51 | $152 |